~$200
Compounded Price / Mo
what people paid during the shortage
~$1,800
Brand Price / Mo
Wegovy list; ~$1,000-1,600 for the others
May 2025
Cheap Version Shut Off
last compounding deadline after shortage "resolved"
9×
The Price Jump
roughly what patients faced overnight
The Price Cliff — What People Pay Per Month
Market Data · 2025The whole story is in this one picture. During the shortage, a compounding pharmacy could legally make the same active drug and sell it for around $200 a month — and many insurers covered it. When the cheap version was shut off, patients were pushed back to the brand-name list price, which is roughly nine times higher. Lilly's cash-pay vials sit in between, but only for some doses.
How It Worked — In Four Plain Steps
T1 · FDA RulesNone of this was a loophole or a scam — it was the law working exactly as written. There's a specific rule that kicks in when a drug is officially "in shortage." Understanding that one rule explains the whole rise and fall.
1. Demand Exploded
2022
Ozempic, Wegovy, Mounjaro and Zepbound took off faster than Novo Nordisk and Eli Lilly could make them. In 2022 the FDA placed semaglutide and tirzepatide on its official Drug Shortage List — a formal declaration that supply couldn't meet demand.
2. The Shortage Rule
Legal
Federal law (the FD&C Act) says that while a drug is on the shortage list, licensed compounding pharmacies are allowed to make their own copies of it — so patients aren't left without medicine. State-licensed 503A pharmacies and FDA-registered 503B outsourcing facilities both stepped in. This is a real, intended safety valve.
3. Cheap Access Bloomed
~$200/mo
Compounders and telehealth platforms (Hims, Ro, and others) sold the compounded versions for ~$200/month vs $1,000-1,800 brand. Millions of people got on the drug, lost weight, and brought blood sugar and blood pressure down — many for the first time, and often with insurance helping.
4. The Shortage "Ended"
The Catch
Once the makers caught up, the FDA declared the shortages resolved (tirzepatide Dec 2024, semaglutide Feb 2025). The instant a drug comes off the shortage list, the compounding permission disappears — by law. Compounders were given short wind-down deadlines, then had to stop. The cheap version became illegal to sell, and prices snapped back to brand.
The Timeline — How Fast the Door Closed
T1 · FDA / Court RecordThe official dates, in order. Notice how quickly access went from "legal and cheap" to "shut down" once the makers caught up — and the final step that aims to make sure it never comes back.
| Date | What Happened | Effect on Access |
|---|---|---|
| 2022 | FDA puts semaglutide & tirzepatide on the Drug Shortage List |
Compounding becomes legal |
| 2022-2024 | Compounders & telehealth sell copies at ~$200/mo |
Cheap & widely available |
| Dec 19, 2024 | FDA removes tirzepatide from the shortage list |
Clock starts ticking |
| Feb 21, 2025 | FDA declares semaglutide shortage resolved |
Clock starts ticking |
| Feb-Mar 2025 | Tirzepatide compounding deadlines hit (503A Feb 18, 503B Mar 19) |
Cheap tirzepatide shut off |
| Apr 24, 2025 | Federal court denies compounders' injunction |
Last legal challenge fails |
| Apr-May 2025 | Semaglutide compounding deadlines hit (503A Apr 22, 503B May 22) |
Cheap semaglutide shut off |
| Apr 30, 2026 | FDA proposes to permanently bar these drugs from bulk compounding |
Door bolted shut |
The pattern, plainly: the shortage rule let cheap copies exist, millions came to rely on them, and the moment the brand-makers could supply the market themselves, the cheap option was removed by law — and the 2026 proposal aims to keep it from ever returning. Whether that's the system protecting safety or protecting prices is the heart of the debate (see "Both Sides" below).
What It Costs Now — Your Real Options
Market Data · 2025-26With the cheap compounded version gone, here's what's actually left for someone who needs these drugs — from the (now illegal) bargain to the brand-name sticker price, and the in-between options that exist today.
Gone
Compounded GLP-1
~$200
/ month (no longer legal)
Shut off in 2025
The option millions relied on
The option millions relied on
Cheapest Legal
Lilly / Novo Cash Vials
$350-500
/ month, self-pay
LillyDirect / NovoCare
Lower doses; the makers' answer to compounders
Lower doses; the makers' answer to compounders
Best If Covered
Brand + Insurance
$0-100
/ month copay
If your plan covers it
Many plans exclude weight-loss use; Medicare won't
Many plans exclude weight-loss use; Medicare won't
Sticker Price
Brand, No Coverage
$1,000-1,800
/ month list
Wegovy ~$1,800
Ozempic/Zepbound/Mounjaro ~$1,000-1,600
Ozempic/Zepbound/Mounjaro ~$1,000-1,600
Where It Stands Now — If You Need These Drugs
T4 · Practical GuidanceIf you or someone you love got cut off, here are the legitimate paths that still exist as of 2026. Not medical advice — a map of the real options to take to your doctor.
Cash Vials
LillyDirect / NovoCare
The drugmakers' own self-pay programs sell single-dose vials for roughly $350-500/month — far below the brand pen price, though usually only for lower doses. This is the cheapest fully-legal route for most people now.
Fight the Coverage
Appeal & document
If insurance dropped you, a documented medical case (diabetes, prediabetes, blood pressure, prior results) plus a doctor's prior-authorization appeal sometimes restores coverage. Coverage for diabetes is far more common than for weight loss alone.
Manufacturer Help
Savings cards
Lilly and Novo both run copay-savings and patient-assistance programs. They exclude government insurance (Medicare/Medicaid) but can cut commercial-insurance costs sharply for those who qualify.
Beware
Gray-market sellers
With the legal cheap option gone, unregulated overseas and "research-only" sellers are filling the gap. These are not the licensed compounders from the shortage era — purity and dosing are unverified, and it's risky. If you go this route, understand you're fully on your own.
Both Sides — Was This Safety, or Profit?
T1 · FDA + Industry vs AccessThis is genuinely contested, so here are both cases as fairly as they can be put. Read them and decide for yourself.
The Establishment Case (FDA & Makers)
"It's about safety and the law"
The shortage really did end — Lilly and Novo invested billions in new manufacturing. The law is explicit: compounding is only allowed during a shortage, full stop. The FDA also logged real safety problems with some compounded versions: dosing errors, unapproved salt forms (e.g. "semaglutide sodium"), and product from facilities it doesn't inspect. Its job, they argue, is to make sure people get the tested, consistent drug — not a cheaper copy of unknown quality.
The Access Case (Patients & Compounders)
"The timing protects prices, not people"
Millions were stabilized on an affordable drug, then cut off on a calendar date — not because it stopped working, but because the brand-makers could now sell it themselves at 5-9× the price. The Outsourcing Facilities Association sued, calling the shortage call "reckless and arbitrary," and argued supply was still tight in places. Critics note the makers gain enormously from killing the cheap competition — and the April 2026 move to permanently bar compounding removes the safety valve even if shortages return. Safety concerns, they say, could be fixed with regulation — not a total shutdown.
What's Not in Dispute
The facts everyone agrees on
The shortage was real. The compounding was legal while it lasted. Millions got affordable access. That access ended by law once the shortage was declared over. Prices jumped sharply. Compounders lost in court. And the FDA is moving to keep these drugs off the bulk-compounding list permanently. Those are the agreed facts — the disagreement is only about why, and whether it was right.
The Human Cost & Who's Who
Real-World Impact
Behind the policy are real people. The numbers are dramatic, but the human side is the point: people who got healthy on an affordable drug, then lost it overnight. Here's who was affected and who the players are.
The Patient Cut Off
The Real Cost
A representative, real story: someone gets on compounded GLP-1 during the shortage, covered by insurance at the cheaper price. They lose 30+ pounds. Blood sugar normalizes. Blood pressure drops. Then the shortage is declared over, the compounder is shut down, insurance drops the now-pricier brand — and they can't afford it. The health gains start unwinding through no fault of their own. Multiply by millions.
Dr. Ashley Froese, MD
Independent MD
The independent clinician voice on the GLP-1 / peptide class. Board-certified family-medicine physician (Direct Primary Care, Mesa AZ) who runs the This Is Not Covered education channel — covering dosing, access, and the compounding situation from outside the drugmaker/FDA frame. A useful non-establishment lens on what changed for patients.
The Compounders
Sued & Lost
The Outsourcing Facilities Association — the trade group for 503B compounding pharmacies — sued the FDA twice (over tirzepatide in Oct 2024, semaglutide in early 2025), calling the shortage-end determination "reckless and arbitrary" and arguing supply was still tight for many patients. A federal court denied their injunction on April 24, 2025. They lost; the shutdown stood.
Who Gains, Who Loses
Follow the $
Winners: Eli Lilly and Novo Nordisk — the cheap competition is now illegal, and they capture the market at full price. Losers: patients pushed off the drug, and the compounders/telehealth firms shut down. The makers point to billions invested in supply and real safety oversight; critics point to the obvious commercial windfall. Both can be true at once — that's why it's contested.
Confused by the Whole Thing? Start Here.
For about two years, the weight-loss and diabetes drugs everyone's talking about — Ozempic, Wegovy, Mounjaro, Zepbound — were available cheap and legal because of an official shortage. Then the shortage was declared over, the cheap versions were shut down by law, and the price jumped back to over a thousand dollars a month. Here's the plain-English version.
What these drugs are
GLP-1 drugs — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). Weekly shots that curb appetite and steady blood sugar. They genuinely work: big weight loss, better diabetes control. That's why demand exploded.
Why it got cheap
When the makers couldn't keep up, the FDA officially declared a shortage. By law, a shortage lets licensed pharmacies make their own copies so patients aren't left without. Those copies sold for about $200/month instead of $1,000+.
Why it got cut off
Once the makers caught up, the FDA declared the shortage over — and the moment that happens, the copying permission ends automatically. Pharmacies got short deadlines, then had to stop. The cheap version became illegal to sell. Prices snapped back to brand.
Was it legal?
Completely legal the whole time — that's what stings. The cheap drug wasn't a scam or a knockoff; it was allowed by the shortage rule. It only became "illegal" because a date on a list changed, not because anything about the drug changed.
So was it a scam?
Depends who you ask — and both sides have a point. The makers and FDA say the shortage genuinely ended and the law required the shutdown, with real safety concerns about some copies. Patients and compounders say the timing conveniently killed cheap competition right when the brands could cash in. The facts are agreed; the motive is what's argued.
Common Questions, Honest Answers
The questions people actually ask once they realize what happened — answered plainly, both sides.
Was the cheap version fake or a knockoff?
No. It was the same active drug, made by licensed pharmacies under a specific federal law that allows it during a shortage. The FDA did flag safety concerns with some compounders (wrong doses, unapproved salt forms, uninspected facilities) — real issues — but the legitimate ones were making the genuine medicine at a fraction of the price.
Why did it become illegal overnight?
Because the law ties compounding directly to the shortage list. The day a drug comes off that list, the permission to compound it ends — automatically. The FDA gave short wind-down windows (weeks to a couple months), then enforcement kicked in. Nothing about the drug changed; only its status on a list did.
Why is the brand version so expensive?
U.S. list prices run roughly $1,000-1,800/month. The makers point to R&D and manufacturing costs; critics point to the lack of competition and price negotiation in the U.S. Either way, with the cheap copies gone, the brand price is now the floor for most people.
Did the makers do anything wrong?
Legally, no — they followed the rules and invested heavily in supply. The criticism is about timing and incentive: ending the shortage killed their cheap competition and let them capture the market at full price, and they're pushing to make the compounding ban permanent. Whether that's prudent supply management or anti-competitive is the honest debate.
My insurance covered it before and now won't. Why?
Many plans covered the cheaper compounded version but won't cover the pricey brand for weight loss (diabetes coverage is more common). When the cheap option vanished, a lot of people effectively lost coverage overnight. Appealing with a documented medical case sometimes works — see "Where It Stands Now" above.
Can it come back if there's another shortage?
That's exactly what the April 2026 FDA proposal targets — it would permanently bar these drugs from bulk compounding, so even a future shortage might not reopen the cheap path. Critics call that removing the safety valve; the FDA frames it as a clinical/safety judgment.
What can I actually do right now?
Check the makers' cash-pay vials (LillyDirect / NovoCare, ~$350-500/mo), appeal your insurance with a documented medical case, and look at manufacturer savings cards. Be wary of unregulated overseas/"research" sellers that popped up to fill the gap — those are not the licensed shortage-era compounders. See "Where It Stands Now" above.
Key Takeaways
- During the 2022-2024 shortage, GLP-1 drugs were legally available compounded for ~$200/month vs $1,000-1,800 brand.
- The cheap option existed only because of the shortage rule — legal while the drug was on the FDA shortage list, automatically illegal once it came off.
- FDA declared the shortages over (tirzepatide Dec 2024, semaglutide Feb 2025); compounding was shut down by May 2025.
- Compounders sued and lost (April 2025); the FDA is moving to permanently bar compounding even in future shortages (April 2026).
- Both sides are real: genuine safety/legal grounds AND a massive commercial windfall for the brand-makers. The facts are agreed; the motive is what's debated.
- If you were cut off: cash vials (~$350-500), insurance appeals, and savings cards are the legitimate paths left.